Lanopepden

Drug Profile

Lanopepden

Alternative Names: 1322322; GSK 1322322; GSK-1322322B; GSK-1322322J; GSK-322; Lanopepden mesylate

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Antibacterials; Cyclopentanes; Heterocyclic bicyclo compounds; Hydroxamic acids; Oxazines; Propionic acids; Pyrazines; Pyrimidines; Small molecules
  • Mechanism of Action Peptide deformylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Bacterial infections

Most Recent Events

  • 26 Jan 2015 GlaxoSmithKline withdraws a phase I pharmacokinetics/pharmacodynamics trial in Healthy volunteers in USA (NCT01953809)
  • 26 Jan 2015 GlaxoSmithKline terminates a pharmacokinetics and safety phase I trial in Healthy volunteers (including those with Japanese ethnicity) in USA (NCT01818011)
  • 01 Jan 2015 GlaxoSmithKline withdraws phase I trial in Bacterial infections in USA (NCT01803399)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top